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The association between cell proliferation and the malignant potential of colon cancer is not well understood. Here, we evaluated this
association using a colon-specific gene proliferation signature (GPS). The GPS was derived by combining gene expression data
obtained from the analysis of a cancer cell line model and a published colon crypt profile. The GPS was overexpressed in both
actively cycling cells in vitro and the proliferate compartment of colon crypts. K-means clustering was used to independantly stratify
two cohorts of colon tumours into two groups with high and low GPS expression. Notably, we observed a significant association
between reduced GPS expression and an increased likelihood of recurrence (Po0.05), leading to shorter disease-free survival in both
cohorts. This finding was not a result of methodological bias as we verified the well-established association between breast cancer
malignancy and increased proliferation, by applying our GPS to public breast cancer data. In this study, we show that reduced
proliferation is a biological feature characterizing the majority of aggressive colon cancers. This contrasts with many other carcinomas
such as breast cancer. Investigating the reasons underlying this unusual observation may provide important insight into the biology of
colon cancer progression and putative novel therapy options.
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Defective regulation of cell proliferation is a fundamental feature
of cancer. By providing a genome-wide insight, microarray
technology has revealed that conserved tumour expression
patterns include many proliferation-associated genes termed as
‘proliferation signatures’. In most cancers, an increased expression
of proliferation signatures has been associated with enhanced
malignancy (Rosenwald et al, 2003; Krasnoselsky et al, 2004; Dai
et al, 2005) suggesting cell proliferation as a driving force for
cancer progression. Breast cancer is a typical example where the
hyper-proliferative nature of more aggressive subtypes has been
confirmed by array-based proliferation assays (Sorlie et al, 2001;
Dai et al, 2005). These studies have also proved the superiority
of cell proliferation analysis by microarrays over conventional
methods regarding its objectivity and because of the assessment
of multiple genes (Paik et al, 2004; Glinsky et al, 2005; Whitfield
et al, 2006).
In colorectal cancer (CRC), the impact of tumour proliferation
rate on malignancy is unclear because the conventional prolifera-
tion markers have produced conflicting results (Supplementary
Figure 1). To date, no proliferation signature has been established
to address such an association.
To investigate the association between proliferation and
aggressiveness of colon cancer, we designed a colon-specific gene
proliferation signature (GPS) that was derived from common
expression patterns of an in vitro CRC model, and of human
colon crypt compartments as published by Kosinski et al (2007).
The GPS was applied to evaluate two independant cohorts of
colonic tumours and revealed an inverse relationship between
tumour cell proliferation and unfavourable clinico-pathological
parameters.
MATERIALS AND METHODS
Cell cultures
The following 10 CRC cell lines were used: DLD-1, HCT-8, HCT-
116, HT-29, LoVo, Ls174T, SK-CO-1, SW48, SW480 and SW620
(ATCC, Manassas, VA, USA). Cells were cultivated in a-MEM
supplemented with 10% foetal bovine serum, 100IUml
 1 peni-
cillin and 100mgml
 1 streptomycin (GIBCO-invitrogen, CA, USA).
Two cell cultures were established for each cell line for RNA
preparation. The first culture was harvested at semi-confluence
(50–60%) when cells were actively cycling. Cells in the second
culture were harvested 48h after reaching full confluence, when
cells were slow-growing. A replicate experiment was performed to
obtain RNA for dye-reversed hybridisations.
Patients
Tumours from two cohorts of colon cancer patients were analysed.
Patient follow-up was a minimum of 5 years. Disease-free survival
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s(DFS) was calculated from surgery to the date of distant
disease recurrence. Patients with rectal cancer, patients for
whom the date of recurrence was unknown or received
pre-operation adjuvant therapy were not included in this study.
Cohort A consisted of 108 New Zealand patients, who underwent
surgery at Dunedin and Auckland hospitals between 1995
and 2000, and included all disease stages. Thirty patients received
5-FU-based post-operative adjuvant chemotherapy. Ethical ap-
proval was obtained from the Ethics Committee, Otago University.
Cohort B consisted of a group of 37 stage II German patients,
who underwent surgery at the Technical University of Munich
between 1995 and 2001. None of the patients received adjuvant
therapy. Clinico-pathologic variables of both cohorts are sum-
marised in Table 1.
Array preparation and gene expression analysis
Cohort A tumours and cell lines Gene expression profiling of
cohort A tumours and cell lines was performed using arrays
spotted with the MWG 30K Oligo Set (MWG Biotech, NC, USA).
RNA was extracted from cell lines and fresh-frozen tissues, using
Tri-Reagent (Progenz, Auckland, NZ) and purified using RNeasy
mini columns (Qiagen, Victoria, Australia). Ten micrograms of
total RNA were oligo-dT primed and cDNA synthesis was carried
out in the presence of aa-dUTP and Superscript II RNase H-
Reverse Transcriptase (Invitrogen, CA, USA). Cy dyes were
incorporated into cDNA using the indirect amino-allyl cDNA
labelling method. A pooled RNA sample derived from a mixture of
12 cell lines was used as a reference for all hybridisations.
The Cy5-dUTP-tagged cDNA from an individual colorectal cell
line or tissue sample was combined with Cy3-dUTP-tagged cDNA
from the reference sample. The mixture was then purified using a
QiaQuick PCR purification kit and co-hybridised to a microarray.
Duplicate hybridisations for cell lines were performed following
dye reversal.
After scanning with a GenePix 4000B microarray scanner (Axon,
CA, USA), the foreground intensities from each channel were
log2-transformed and normalised using the SNOMAD software
(Colantuoni et al, 2002). Normalised values were collated and
filtered using BRB-Array Tools version 3.6.0-b_3 (by Dr Richard
Simon and Amy Peng Lam, National Cancer Institute). Genes of
low signal intensity, or for which more than 20% of measurements
across tissue samples or cell lines were missing, were excluded
from further analysis.
Cohort B tumours Total RNA was prepared from each tumour
using the RNeasy mini kit (Qiagen, Hilden, Germany). Ten
micrograms of total RNA were used to synthesise double-stranded
cDNA with SuperScript II reverse transcriptase (Gibco-Invitrogen,
NY, USA) and an oligo-dT-T7 primer (Eurogentec, Koeln,
Germany). The biotinylated cRNA was synthesised from the
double-stranded cDNA using the Promega RiboMax T7-kit
(Promega, Madison, WI, USA) and Biotin-NTP labelling mix
(Loxo, Dossenheim, Germany). The biotinylated cRNA was then
purified and fragmented. The fragmented cRNA was hybridised to
Affymetrix HGU133A GeneChips (Affymetrix, Santa Clara, CA,
USA) and stained with streptavidin–phycoerythrin. The arrays
were scanned with an HP-argon laser confocal microscope
and the digitised image data were processed using the Affymetrix
s
microarray suite 5.0 software. Background correction and normal-
isation were performed in the R computing environment
(Ihaka and Gentleman, 1996) using the robust multi-array average
algorithm.
Quantitative real-time PCR
The expression of seven randomly selected genes from the GPS
(MAD2L1, POLE2, CDC2, MCM6, MCM3, TOPK and GMNN) was
validated by quantitative real-time PCR (qRT–PCR) on an ABI
Prism 7900HT Sequence Detection System using cell line cDNA
and Taqman Gene Expression assays (Applied Biosystems, CA,
USA). Relative fold changes were calculated using the 2
 DDCT
method (Livak and Schmittgen, 2001) with Topoisomerase 3A as
the internal control. Reference RNA was used as the calibrator to
enable comparison between different experiments.
Immunohistochemical analysis
Ki-67 immunohistochemistry was performed on 40 cohort
A tumours for which paraffin blocks were available,
and an additional set of 33 rectal/rectosigmoid tumours
was included to increase statistical power. Antigens were
retrieved on 4-mm sections in boiling citrate buffer (pH 6). Primary
Table 1 Clinico-pathologic characteristics of two cohorts of colon
cancer patients and associations with the GPS
Numbers
Cohort A Cohort B
Parameters Cohort A Cohort B (P-value)
a (P-value)
a
Age
b
oMean 49 20 0.33 0.79
4Mean 59 17
Sex
Male 62 21 0.56 0.74
Female 46 16
Differentiation
Well/moderate 83 22 0.17 0.20
Poor 25 15
Disease stage
I1 2 0 0.015 NA
II 64 37
III 29 0
IV 3 0
Vascular invasion
Yes 9 1 0.065 NA
No 99 36
Lymphatic invasion
Yes 23 3 0.018 1
No 85 34
Lymphocyte infiltration
Nil/mild 53 9 0.67 0.48
Moderate 42 17
Prominent 13 11
Margin
Infiltrative 56 NA 0.84 NA
Expansive 52
Chemotherapy
Yes 30 0 0.08 NA
No 78 37
Recurrence at 5 years
Yes 24 16 0.021 0.005
No 84 21
Total 108 37
Abbreviations: GPS¼gene proliferation signature; NA¼not applicable.
aA Fisher’s Exact test or Kruskal–Wallis test were used for testing association
between clinico-pathologic parameters and the dichotomous GPS variable.
bAverage age 68 and 63 years for cohort A and B patients, respectively. Bold
numbers represent significant P-values.
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santibody (MIB-1, DakoCytomation, Denmark; dilution 1:50)
was detected using the EnVision system (Dako EnVision)
and the DAB substrate kit (Vector Laboratories, CA, USA).
Five high-power fields were counted by two observers in
a blinded manner. The Ki-67 proliferation index (PI) was
presented for each tumour as the percentage of positively
stained nuclei.
Statistical analysis
The K-means clustering method was applied to stratify clinical
samples on the basis of the GPS expression level using the TIGR
MeV 4.0 software (Saeed et al, 2003). Using Pearson uncentered
correlation, tumours from each cohort were assigned to two
clusters (i.e., K-means clustering with K¼2, 1000 iterations of
clustering) with the threshold of occurrence in the same cluster set
to 80%. The consensus clusters each contained tumours with
similar GPS expression, resulting in two patient groups differing in
their GPS levels. Either Fisher’s exact test or the Kruskal–Wallis
test was then used to evaluate the associations between the
dichotomous GPS variable and clinico-pathologic parameters.
Statistical analyses were performed using SPSS 15.0.0 (SPSS Inc.,
Chicago, IL, USA). For Ki-67 analysis, tumours were stratified into
two clusters with the mean Ki-67 value as a cutoff point.
The gene set comparison function from the BRB-Array tools
software was used to analyse the GPS for differential expression
among subgroups defined by the clinico-pathologic variables. The
GPS was considered to have a higher-than-expected number of genes
differentially expressed (DE) between the classes being compared if
the Kolmogorov–Smirnov (KS) resampling P-value was less than
0.005 (default value). The distribution of KS statistics was obtained by
100000 iterations of the random resampling process.
Disease-free survival was plotted using the method of Kaplan
and Meier, and a log-rank test was used to test for differences in
survival time between defined clusters of patients according to the
GPS or Ki-67 PI. A multivariate Cox proportional hazards model
was developed using forward stepwise regression with predictive
variables that were significant in the univariate analysis. Cox
multivariate regression was not relevant for measuring the
performance of the GPS in cohort B, as this population of tumours
included only stage II colon cancers.
RESULTS
Derivation of a GPS
To identify a set of genes whose expression was associated with
tumour cell proliferative activity, two proliferation-based systems
were analysed and integrated as described below and illustrated in
Figure 1.
A. Gene expression analysis of a CRC in vitro model The in vitro
system involved identification of genes that were to reflect the
proliferative activity of CRC cell lines. Genes DE between
exponentially growing (nonconfluent) and growth-inhibited (con-
fluent) cell lines were identified (Figure 1A–C). Firstly, DE genes
between Cy5-labelled nonconfluent and confluent samples were
identified by statistical analysis of microarray (two-class paired,
FDRo1%; Tusher et al, 2001). Secondly, DE genes between Cy3-
labelled nonconfluent and confluent samples (biological replicates)
were identified using the same approach. To minimise gene-
specific dye bias and other sources of variation, only genes that
were present in both SAM-generated gene sets were selected. The
gene set was further reduced to genes whose expression was
consistently altered in the same direction in at least 8 out of 10 cell
lines, yielding a total 881 DE genes with known annotation
(Figure 1D).
Gene ontology (GO) analysis showed that categories related
to cell cycle and DNA metabolism were the most over-represented
biological themes among the DE genes, mainly because of
genes that were overexpressed in exponentially growing cells
(Po10
 5).
B. Gene expression profile of the proliferative compartment of colon
crypts The second gene set used for the design of a GPS was
based on the physiological expression profile of human colon
crypts. Kosinski et al (2007) compared the proliferative bottom
part of crypts with the differentiated crypt top, and identified 299
DE genes highly expressed in the proliferative bottom (Figure 1E).
The GO terms that were over-represented within this gene list were
related to cell proliferation and renewal, consistent with the
physiological function of the bottom crypt compartment.
C. Definition of the GPS To define a final GPS enriched in key-
proliferative genes, the in vitro and in vivo-derived DE gene lists
were screened for common genes (Figure 1F). Thirty-six genes
were found to be overexpressed in both exponentially growing
CRC cell lines and the proliferative crypt compartment. These
genes were defined as GPS that included 15 cell cycle-related genes
(Supplementary Figure 2).
The expression of 7 genes randomly selected from the 15 cell
cycle-related genes was validated by qRT–PCR on the cell line
cDNAs. A close correlation between qRT–PCR and array data was
observed (Supplementary Table 2).
Classification of colon tumours according to the GPS
expression level
To investigate the association between the GPS and patient
parameters, expression values of the GPS genes were first obtained
from the array-generated expression profiles. Expression data were
available for all 36 genes in cohort A, and 35 genes (except CDCA5)
in cohort B tumours. For each cohort, tumours were split into two
consensus clusters on the basis of their GPS expression using
K-means clustering. Tumours with relatively high or low GPS
expression were defined as having high or low proliferative
activity, respectively (Figure 1G).
Reduced expression of the GPS is associated with
unfavourable clinico-pathologic variables
Intriguingly, we observed an association between reduced GPS
expression and an increased risk of recurrence in both cohorts
(Table 1). Groups with reduced GPS expression were significantly
enriched for recurrent tumours (P¼0.021 and 0.005 for cohort A
and B, respectively). In cohort A, reduced GPS expression was also
associated with higher disease stage (P¼0.015). Further, reduced
GPS expression was significantly more frequent in cohort A
tumours with lymphatic invasion compared with those without
lymphatic invasion (P¼0.018). Gene set comparison analysis
confirmed that GPS contained a higher-than-random proportion
of DE genes among subgroups with clinico-pathologic parameters
for which a significant association with the GPS was found in
nonparametric tests (Supplementary Table 1).
Reduced GPS expression is associated with shorter DFS in
colon cancer
To examine whether a difference in cell proliferation determined
by the GPS may be associated with time to recurrence, DFS was
plotted for low GPS and high GPS tumours (Figure 2). DFS was
significantly shorter in patients with reduced GPS expression
(P¼0.033 and 0.011 for cohort A and B patients, respectively;
Figure 2A and C). This association remained significant in cohort
A proliferation signature in colon cancer
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Figure 2B).
If prolifetative activity is a crucial factor influencing DFS,
then a GPS consisting of only genes directly implicated in
cell cycle process should be sufficient to separate patients into
groups with different survival rates. Therefore, the GPS was
reduced to the 15 cell cycle-regulated genes and survival analysis
was repeated. The modified GPS stratified patients into groups
that differed in their DFS more stringently (P¼0.022 and 0.003
for cohort A and B patients, respectively; Figure 2D–F) than
the original GPS including all 36 genes. Therefore, colon cancer
patients with tumours of lower proliferative activity are more
likely to recur.
When the parameters predicting patient outcome in univariate
analysis were investigated in a multivariate model, disease stage was the
only independant predictor of 5-year DFS in cohort A (Table 2).
Increased GPS expression is associated with shorter DFS in
breast cancer
As the association between reduced GPS expression and poor
colon cancer prognosis was an unexpected finding, we tested the
validity of our GPS on public array data from two independant
breast cancer cohorts. Using these data, an association between
increased proliferation and bad outcome has been established
earlier (van de Vijver et al, 2002; Pawitan et al, 2005).
For each breast cancer data set, patients were stratified into two
groups with either low or high GPS expression and their DFS was
plotted. In both data sets, patients with increased GPS expression had
significantly shorter DFS compared with patients with reduced GPS
expression (Po0.0001; Figure 3), confirming the previously established
association. Therefore, the association between low proliferation and
bad colon cancer outcome is not the result of biased methodology.
Detection of disease-free
survival difference between
the two defined groups
Stratification of colon cancers
into high and low GPS groups
by K-means clustering method
Identification of the GPS
299 overexpressed genes
in proliferation zone
881 common genes
between two gene sets
First DE gene set Second DE gene set
SAM SAM
Proliferation
zone
Differentiation
zone
Normal colon crypt
Reference
cDNA
Reference
cDNA
Biological replicates
Figure 1 Overview methodology. A gene proliferation signature (GPS) was derived by combining the gene expression data from the analysis of a cell line
model and colon crypts. (A) Ten colorectal cancer cell lines were cultured and harvested at semi-confluence and full confluence. Each cell culture was
performed in duplicate. (B) Using a reference design, a mixture of sample and reference dye-labelled cDNAs was hybridised to a 30K Oligo array. Dye
orientation was reversed for biological replicates. (C) Statistical analysis of microarrays (SAM) was performed to identify differentially expressed (DE) genes
between two stages of growth in cultures. Two gene sets were generated through the analysis of samples with identical dye labelling. (D) Only 881 genes
that were presented in both SAM-generated gene sets and DE gene sets were selected. (E) Human colon crypt profiling resulted in identification of 299 DE
genes with overexpression in the proliferation zone compared with the differentiation zone. (F) The GPS was generated by taking the overlapping genes
between D and E gene sets. (G) Two cohorts of colon cancer patients were stratified into low and high groups according to the GPS expression using
K-means clustering method. (H) Disease-free survival difference was calculated between the two defined groups.
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Ki-67 PI ranged from 25 to 96%, with a mean value of 76.3±17.5
and a median value of 81.8%. When these 73 patients were
stratified into two groups differing in their GPS expression, a
significant difference in DFS was apparent (P¼0.01; Supplemen-
tary Table 3). However, when patients were stratified into two
groups according to the mean Ki-67 PI, the DFS of the group with a
low PI was similar to that with a high PI (P¼0.55; Supplementary
Table 3). Furthermore, when analysis was limited to patients with
the highest and the lowest Ki-67 values, no statistical difference in
DFS was observed (data not shown). No correlation was found
between the Ki-67 PI and mean GPS expression of tumours
(Spearman R¼0.06; P¼0.63).
DISCUSSION
Cancer is regarded as a proliferative disorder, where a selective
growth advantage is believed to crucially contribute to its
development and progression. Supporting this concept are many
studies that have shown an association between poor clinical outcome
and high expression of proliferation-associated genes (Krasnoselsky
et al, 2004; Dai et al, 2005; Kirschner-Schwabe et al, 2006).
Our study is the first to report an inverse relation between
cancer malignancy and the expression of a multi-gene proliferation
signature. In two independant cohorts of colon cancer patients, we
observed an association between an increased recurrence risk
and the reduced expression of a GPS. This finding challenges the
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Figure 2 Disease-free survival analysis of colon cancer patients stratified into high and low groups according to the GPS expression or 15 cell cycle-
regulated genes included in the GPS. In both cohorts, the low GPS groups had significantly shorter DFS compared with the high GPS groups (A and C). This
difference was more significant when only cell cycle-regulated genes were used to stratify patients (D and F). The same association was found when the
analysis was limited to those cohort A patients who received no adjuvant therapy (B and E).
Table 2 Cox regression analysis of determinants of DFS in cohort A
cancer patients
Univariate analysis
Multivariate analysis
a
Parameters P-value
b HR (CI)
c P-value
Disease stage
(I+II vs III+IV)
o0.001 4.5 (1.8–10.8) 0.001
Lymphatic invasion
(  vs +)
o0.001 — —
Vascular invasion
(  vs +)
0.012 — —
Margin
(expansive vs infiltrative)
0.015 — —
GPS expression
(high vs low)
0.022 — —
Abbreviation: DFS¼disease-free survival
aFinal results of Cox regression analysis
using a forward stepwise method (enter limit¼0.05, remove limit¼0.10).
bLog-rank
test P-value.
cHazard ratio (HR) determined by Cox regression model; confidence
interval (CI)¼95%.
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poor prognosis, and suggests that low proliferative activity is a
biological feature of the majority of aggressive colon cancers.
The GPS we designed is highly likely to directly reflect the
proliferative state of a tumour, as it was derived from both human
colon crypts and an in vitro CRC model. All genes included in the
GPS were overexpressed in actively proliferating cells of the both
systems. With respect to the in vitro system, the comparison of
exponentially growing cancer cells with contact-inhibited cancer
cells has limitations; however, well established evidence indicates
that many tumour cell lines maintain a variable degree of density-
dependant growth suppression that is characteristic of the
stationary phase (Couldwell et al, 1992; Steinman et al, 2003;
Kuhn et al, 2004; Motti et al, 2005). Ten CRC cell lines were
included to ensure an overall growth suppression, and only genes
were considered that were altered in at least 80% of the cell lines.
By the inclusion of only DE genes that overlapped with the human
colon proliferation signature, the final GPS consisted of genes that
strongly correlate with both colon cancer cell growth and
physiological colon proliferation. Consistent with this, ontology
analysis indicated that proliferation-associated genes represent the
main biological theme in both the in vitro and the in vivo system.
Further evidence supporting the association of the GPS with cell
proliferation stems from a considerable overlap in genes or gene
families identified between our GPS and other proliferation
signatures defined for tumours of the breast (Perou et al, 1999,
2000), ovary (Welsh et al, 2001), liver (Chen et al, 2002), acute
lymphoblastic leukaemia (Kirschner-Schwabe et al, 2006), neuro-
blastoma (Krasnoselsky et al, 2004), lung squamous cell carcinoma
(Inamura et al, 2005), head and neck (Chung et al, 2004), prostate
(LaTulippe et al, 2002) and stomach (Hippo et al, 2002).
Comparing these published data, Whitfield et al (2006) identified
a core set of genes common to various proliferation signatures. As
expected, these genes (MYBL2, PLK1, CDC2 and MCM genes) are
also contained within our GPS (see Supplementary Figure 2),
reflecting the universal mechanisms that govern human cell
division. Indeed, by reanalysis of public breast cancer data, our
GPS was shown to perform properly in other cancer types as well.
Therefore, our GPS appears to be a reliable tool for the assessment
of proliferation in colonic tumours.
Application of our GPS to colon cancer patient data revealed a
robust association between low proliferative activity and increased
likelihood of recurrence. Firstly, the low GPS group had reduced
DFS in two independant cohorts derived from different popula-
tions. Secondly, expression data from the two cohorts were
obtained using two different array platforms, indicating that the
observed association was not subject to methodological bias.
Thirdly, reduced GPS expression in cohort A also correlated with
clinico-pathological variables related to poor outcome (stage,
lymphatic invasion). A possible confounding factor in our study
was the chemotherapy treatment as given in 28% of cohort A
patients. Exclusion of these patients from analysis had no effect on
the association strength, suggesting that proliferation affects
patient outcome independant of adjuvant chemotherapy.
Notably, the observed association was not independant of
tumour stage. In other words, higher disease stages were enriched
for slowly proliferating tumours, but tumours with high GPS
expression were also present. It remains possible, however, that
these fast proliferating tumours had progressed slowly before they
were diagnosed at an advanced stage. It is likely that tumour stage
is a better prognostic factor because the presence of lymph node
and distant organ involvement is a direct manifestation of
metastasis. It is noteworthy that the goal of this study was not to
develop a prognostic tool based on the GPS, but to determine the
nature of the relationship between proliferation and the degree of
malignancy in colon cancer.
Together, the analyses we performed are all consistent with a
marked effect of colon cancer proliferation on the rate of its
recurrence. This is an important finding because studies using
conventional proliferation markers have not been able to establish
a clear-cut association between colon cancer proliferation and
outcome. On account of these reported inconsistencies, we also
performed DFS analysis on the basis of proliferation estimated by
conventional Ki-67 labelling. Unlike the GPS, Ki-67 PI failed to
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Figure 3 Stratification effect of the GPS on two cohorts of breast cancer patients. The heat maps represent the normalised gene expression values of the
GPS genes across samples. Each row represents one gene and each column represents one sample. Colour bars on the top of heat maps represent
proliferation groups (high proliferation is indicated in red, and low proliferation is indicated in green as defined by K-means clustering) and recurrence status
(black, recurrence; grey, nonrecurrence). There is a close correlation between high GPS expression and recurrence in both cohorts. Disease-free survival is
significantly shorter in the high GPS groups compared with the low GPS groups.
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survival (Supplementary Table 3). Although the advantage of
assessing multiple genes as opposed to one proliferation marker
appears obvious, additional parameters are likely to contribute to
the inferior performance of the Ki-67 PI. Ki-67 positivity reflects
the number of cells in cycle, rather than their cycling speed (Endl
and Gerdes, 2000). Furthermore, the visual scoring of Ki-67
positive nuclei is inherently subjective, confounding correlations
particularly in the case of small sample sizes (Barzanti et al, 2000).
It is of interest, however, that a low Ki-67 PI has been associated
with poor outcome in the three studies with the highest statistical
power (i.e., largest sample sizes) (Allegra et al, 2003; Garrity et al,
2004; Hilska et al, 2005).
It is difficult to assess from our data whether slow proliferation
directly enhances the ability of a colon cancer to metastasise or fast
proliferation may be disadvantageous for colon cancers to acquire
metastatic capacity. Although it appears intuitively logical that
accelerated cell division allows for more genetic events required
for progression to accumulate, fast proliferation might also have a
negative impact on a tumour ability to survive and spread. For
example, rapidly growing tumours may elicit a stronger and more
effective immune response. Further, highly proliferative tumours
may contain a lower proportion of cancer stem cells thought to
undergo relatively slow divisions. Alternatively, a high level of
genetic instability may increase the invasive potential of cancer cells
or their resistance towards apoptosis, but may interfere with smooth
replication. Also, hypoxic conditions may slow down the growth rate
of tumours but could promote the onset of epithelial–mesenchymal
transitions leading to invasion. Possible underlying mechanisms are
currently under investigation in our laboratory.
The intriguing finding of an inverse relationship between tumour
proliferative activity and disease aggressiveness suggests that funda-
mental biological differences exist for the mechanisms that drive
disease progression in colon cancer compared with other epithelial
malignancies. The delineation of the underlying processes will be
important not only for the understanding of colon cancer biology, but
also for the design of new therapeutic strategies. In this context, the
development of alternative therapies might be a pertinent issue, given
that current chemotherapeutic agents are usually designed to target
colon cancer progression by killing rapidly proliferating cells.
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